The anti-CD47/CD19 BsAb TG-1801 (NI-1701) has demonstrated strong potential in preclinical studies to elicit ADCP and ADCC in malignant B-cell lines and primary tumor B-cells from patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and several subtypes of NHL (7, 50, 51). This evidence concerns the gene CD47 and non-Hodgkin lymphoma.